Printer Friendly
The Free Library
7,774,290 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

APOMATE WINS FDA APPROVAL.


Byline: Chris Sieroty Staff Writer

CHATSWORTH - Shares of North American North American

named after North America.


North American blastomycosis
see North American blastomycosis.

North American cattle tick
see boophilusannulatus.
 Scientific Inc. gained 13 percent Tuesday after the company announced that its Apomate drug had received orphan drug orphan drug, drug developed under the U.S. Orphan Drug Act (1983) to treat a disease that affects fewer than 200,000 people in the United States. The orphan drug law offers tax breaks and a seven-year monopoly on drug sales to induce companies to undertake the  status from the U.S. Food and Drug Administration.

The drug, which is currently undergoing clinical trials in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area.  and Europe, is intended for the noninvasive diagnosis of cardiac transplant rejection transplant rejection Graft rejection, organ rejection, tissue rejection Immunology The constellation of host immune responses evoked when an allograft tissue is transplanted into a recipient; rejection phenomena may be minimized by optimal matching of MHC antigens .

``We appreciate the thoughtful review by the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 of our orphan drug application and believe that the incentives provided by the orphan drug law are working well to bring new health care opportunities to patients with uncommon diseases,'' said L. Michael Cutrer, president and chief executive officer of North American Scientific, in a statement.

Susan Cruzan, a spokeswoman with the FDA in Washington, explained that ``the designation is to help get drugs on the market that treat orphan conditions - in other words Adv. 1. in other words - otherwise stated; "in other words, we are broke"
put differently
, conditions that affect fewer than 200,000 people in any given year.''

Since the Orphan Drug Act was passed by Congress in 1982, more than 200 drugs and biological products have been brought to market, Cruzan said.

Apomate is currently undergoing the second phase of clinical trials to further refine and optimize the imaging technique prior to a planned third study scheduled to begin in mid-2001, the company said.

Shares of Chatsworth-based North American Scientific Inc. gained $2.50, or 13.16 percent, Tuesday to close at $21.50 on heavy volume of 36,900 shares traded on the Nasdaq exchange.
COPYRIGHT 2000 Daily News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Business
Publication:Daily News (Los Angeles, CA)
Geographic Code:1USA
Date:Dec 6, 2000
Words:244
Previous Article:COOK'S CORNER SOUP'S ON, AND THE TIME IS RIGHT.(L.A. Life)(Recipe)
Next Article:BUSINESS NOTES DIODES, FABTECH ACQUISITION DONE.(Business)
Topics:



Related Articles
Manufacturers applaud quicker federal approvals. (Los Angeles County, California medical device industry)(Special Report: Health Care)
MiniMed Is Recovering From Delay in Diabetes Product Test.(Brief Article)
Medical Firm Gets Shot in Aim From Key Acquisition.(North American Scientific Inc.)(Brief Article)
Developer of Cancer Drug Sues the FDA.(American BioScience Inc.)(Brief Article)
Biomedical Company Left Reeling From Rough Ride.(Brief Article)(Statistical Data Included)
ON A ROLL TECH COMPANIES ALONG THE 101 CORRIDOR AMONG BRIGHT SPOTS.(Business)
FDA APPROVES HOME DRUG TEST KIT : KEY FACTS.(NEWS)
Pouring profits into R&D, Biotech firm seeks payoff. (Corporate Focus).
The politics of Plan B.(Editorials)(FDA decision sparks partisan accusations)(Editorial)
Block Bush's choice.(Editorials)(Clinton and Murray should stand their ground)(Editorial)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles